

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT2868765

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ADRIAN RUSSELL	06/01/2010
Felix Meiser	06/01/2010
Marck Norret	06/01/2010
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ICEUTICA PTY LTD.
<b>Street Address:</b>	One Kew Place, 150 Rouse Boulevard Navy Yard Corporate Center
<b>City:</b>	Philadelphia
<b>State/Country:</b>	PENNSYLVANIA
<b>Postal Code:</b>	19112
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	14284981
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(617) 542-5070
<b>Email:</b>	apsi@fr.com
<b>Correspondent Name:</b>	ANITA L. MEIKLEJOHN
<b>Address Line 1:</b>	FISH & RICHARDSON P.C.
<b>Address Line 2:</b>	P.O.BOX 1022
<b>Address Line 4:</b>	MINNEAPOLIS, MINNESOTA 55440-1022
<b>ATTORNEY DOCKET NUMBER:</b>	31215-0012005
<b>NAME OF SUBMITTER:</b>	MARY FLORCZAK
<b>SIGNATURE:</b>	/Mary Florczak/
<b>DATE SIGNED:</b>	05/23/2014
<b>Total Attachments: 9</b>	
source=MEISERETC#page1.tif	
source=MEISERETC#page2.tif	
source=MEISERETC#page3.tif	
source=MEISERETC#page4.tif	
<b>PATENT</b>	

source=MEISERETC#page5.tif  
source=MEISERETC#page6.tif  
source=MEISERETC#page7.tif  
source=MEISERETC#page8.tif  
source=MEISERETC#page9.tif

# **Deed of Acknowledge & Assignment of Intellectual Property Rights**

Adrian Russell

and

Felix Meiser

and

Marck Norret

and

iCeutica Pty Ltd  
ACN 113 244 152

**Middletons**  
Melbourne office  
Ref: NSIV.PTH.10028271

©Middletons 2010. All rights reserved.

**PATENT**  
**REEL: 032954 FRAME: 0817**

## Deed of Acknowledgment and Assignment of Intellectual Property Rights

Date 2010

By

Adrian Russell of 139 Gladstone Road Rivervale, Western Australia 6103

Felix Meiser of 7 Beecham Road, Mt Claremount, Western Australia 6010

Marck Norret of 26 Stone Crescent Darlington, Western Australia 6070

(collectively, the **Assignors**)

In favour of

iCeutica Pty Ltd ACN 113 244 152 of 52 Fairfield Street, Mt Hawthorn, Western Australia 6016  
(Assignee)

### Background

- A. The Assignors did, in the ordinary course of their respective employment with the Assignee, conceive and/or develop the inventions listed in Schedule 1 (each an **Invention**) which are disclosed and/or claimed in the respective corresponding patent applications also listed or described in schedule 1 (**Patent Applications**).
- B. The Assignors and the Assignee wish to confirm, and to the extent necessary, assign to the Assignee, the Assignors' respective rights, title and interests in the inventions and in the Patent Applications.

### AGREED TERMS

- 1. Notwithstanding anything to the contrary herein, a reference in this Deed to an Assignor assigning rights, title or interest in an Invention or a Patent Application, making an acknowledgment, representation and/or confirmation with respect to an Invention or a Patent Application, refers to those Inventions and Patent Applications, each considered separately, which the Assignor invented solely or jointly with others.
- 2. Adrian Russell and Felix Meiser hereby acknowledge and represent that:
  - (a) the Inventions were conceived by Adrian Russell and Felix Meiser in their respective capacity as an employee of the Assignee and in the ordinary course of their respective ordinary duties of employment by the Assignee; and
  - (b) If and to the extent that the Adrian Russell and Felix Meiser were engaged by any third party concurrently with their respective engagement by the Assignee, conception of the Inventions was entirely outside the scope of their engagement with such third party.
- 3. Marck Norret hereby acknowledges and represent that:

- (a) his work on the Inventions after 1 July 2009 was in his capacity as an employee of the Assignee and in the ordinary course of his/her ordinary duties of employment by the Assignee; and
  - (b) if and to the extent that Marck Norret was engaged by any third party concurrently with his engagement by the Assignee, conception of the Inventions was entirely outside the scope of his engagement by such third party.
- 4. Each Assignor further hereby acknowledges and confirms that all rights, title and interest in the Inventions and Patent Applications, including but not limited to:
  - (a) the right to apply for registration of a Patent Application, and to own all registrations derived therefrom including reissues, extensions, confirmations, re-examinations, and inventor's certificates;
  - (b) the right to sue and claim and retain damages and other remedies, including but not limited to an account of profits, for infringements of and/or wrongful interferences to a Patent Application whether or not such rights arose before the date of this Deed; and
  - (c) all rights, powers, liberties and immunities conferred on the proprietor of the patents or applications relating to a Invention,

(collectively, the "**Assigned Rights**") were transferred and assigned to and vested in the Assignee absolutely at the time of filing each of the Patent Applications.
- 5. To the extent not already assigned, each Assignor hereby assigns to the Assignee his entire respective legal and beneficial right, title and interest in the Assigned Rights.
- 6. Each Assignor agrees to execute all such further documents and do all such further acts necessary to effect the assignment of the Assigned Rights to the Assignee as contemplated by this Deed.
- 7. Each Assignor hereby appoints the Assignee as the Assignor's attorney to do all acts and execute all documents on behalf of the Assignor to the extent necessary to vest the rights in the Assignee as contemplated by this Deed.
- 8. This Deed is governed by and must be construed in accordance with the laws in force in the State of Victoria. The parties submit to the exclusive jurisdiction of the courts of that State and the Commonwealth of Australia in respect of all matters arising out of or relating to this Deed, its performance or subject matter.
- 9. If this Deed consists of a number of signed counterparts, each is an original and all of the counterparts together constitute the same document.

## Schedule 1 – Invention and corresponding Patent Applications

### 1. Invention: Production of encapsulated nanoparticles at high volume fractions

Inventors: Aaron Dodd, Felix Meiser, Marck Norett, Adrian Russell and William Bosch

Patent Applications:

Patent application no. PCT/AU2010/000464, filed on 24 April 2010 in the name of iCeutica Pty Ltd, and priority Australian Patent Application No. 2009901744 filed on 24 April 2009 and US Patent Application 61/172,278, also in the name of iCeutica Pty Ltd (**Provisional Applications 1**) and all patent applications that:

- (i) claim priority from Provisional Applications 1;
- (ii) disclose or claim the Invention or any aspect of it; or
- (iii) comprise continuations, continuations in part, divisions, re-issue or substitution of the patent applications described in paragraphs (i) and (ii) above and application for a substantially similar form of protection for the Invention granted by another country where the essence is that the holder of the protection gains an exclusive right to make, use and sell a product or process.

### 2. Invention: Production of encapsulated nanoparticles at commercial sales

Inventors: Aaron Dodd, Felix Meiser, Marck Norett, Adrian Russell and William Bosch

Patent Applications:

Patent application no. PCT/AU2010/000466, filed on 24 April 2010 in the name of iCeutica Pty Ltd, and priority Australian Patent Application No. 2009901740 filed on 24 April 2009 and US Patent Application 61/172,297 also in the name of iCeutica Pty Ltd (**Provisional Applications 2**) and all patent applications that:

- (i) claim priority from Provisional Applications 2;
- (ii) disclose or claim the Invention or any aspect of it; or
- (iii) comprise continuations, continuations in part, divisions, re-issue or substitution of the patent applications described in paragraphs (i) and (ii) above and application for a substantially similar form of protection for the Invention granted by another country where the essence is that the holder of the protection gains an exclusive right to make, use and sell a product or process.

### 3. Invention: Method for the production of commercial nanoparticle and microparticle powders

Inventors: Aaron Dodd, Felix Meiser, Marck Norett, Adrian Russell and William Bosch

Patent Applications:

Patent application no. PCT/AU2010/000467, filed on 24 April 2010 in the name of iCeutica Pty Ltd, and priority Australian Patent Application No. 2009901747 filed on 24 April 2009 and US Patent Application 61/172,300, also in the name of iCeutica Pty Ltd (**Provisional Applications 3**) and all patent applications that:

- (i) claim priority from Provisional Applications 3;

docs 2775373v3 NSIV

- (ii) disclose or claim the Invention or any aspect of it; or
- (iii) comprise continuations, continuations in part, divisions, re-issue or substitution of the patent applications described in paragraphs (i) and (ii) above and application for a substantially similar form of protection for the Invention granted by another country where the essence is that the holder of the protection gains an exclusive right to make, use and sell a product or process.

**4. Invention: Method for improving the dissolution profile of a biologically active material**

Inventors: Aaron Dodd, Felix Meiser, Marck Norett, Adrian Russell, Matt Callahan and William Bosch

Patent applications:

Patent application no. PCT/AU2010/000465, filed on 24 April 2010 in the name of iCeutica Pty Ltd, and priority Australian Patent Application No. 2009901741 filed on 24 April 2009 and US Patent Application 61/172,301, also in the name of iCeutica Pty Ltd (**Provisional Applications 4**) and all patent applications that:

- (i) claim priority from Provisional Applications 4;
- (ii) disclose or claim the Invention or any aspect of it; or
- (iii) comprise continuations, continuations in part, divisions, re-issue or substitution of the patent applications described in paragraphs (i) and (ii) above and application for a substantially similar form of protection for the Invention granted by another country where the essence is that the holder of the protection gains an exclusive right to make, use and sell a product or process.

**5. Invention: A novel formulation of metaxalone**

Inventors: Aaron Dodd, Felix Meiser, Marck Norett, Adrian Russell and William Bosch

Patent Applications:

Patent application no. PCT/AU2010/000468, filed on 24 April 2010 in the name of iCeutica Pty Ltd, and priority Australian Patent Application No. 2009901743 filed on 24 April 2009 and US Patent Application 61/172,281, also in the name of iCeutica Pty Ltd (**Provisional Applications 5**) and all patent applications that:

- (i) claim priority from Provisional Applications 5;
- (ii) disclose or claim the Invention or any aspect of it; or
- (iii) comprise continuations, continuations in part, divisions, re-issue or substitution of the patent applications described in paragraphs (i) and (ii) above and application for a substantially similar form of protection for the Invention granted by another country where the essence is that the holder of the protection gains an exclusive right to make, use and sell a product or process.

**6. Invention: A novel formulation of meloxicam**

Inventors: Aaron Dodd, Felix Meiser, Marck Norett, Adrian Russell and William Bosch

Patent Applications:

Patent application no. PCT/AU2010/000469, filed on 24 April 2010 in the name of iCeutica Pty Ltd, and priority Australian Patent Application No. 2009901742 filed on 24 April 2009 and US Patent Application 61/172,284, also in the name of iCeutica Pty Ltd (**Provisional Applications 6**) and all patent applications that:

- (i) claim priority from Provisional Applications 6;
- (ii) disclose or claim the Invention or any aspect of it; or
- (iii) comprise continuations, continuations in part, divisions, re-issue or substitution of the patent applications described in paragraphs (i) and (ii) above and application for a substantially similar form of protection for the Invention granted by another country where the essence is that the holder of the protection gains an exclusive right to make, use and sell a product or process.

**7. Invention: A novel formulation of naproxen**

Inventors: Aaron Dodd, Felix Meiser, Marck Norett, Adrian Russell and William Bosch

Patent Applications:

Patent application no. PCT/AU2010/000470, filed on 24 April 2010 in the name of iCeutica Pty Ltd, and priority Australian Patent Application No. 2009901746 filed on 24 April 2009 and US Patent Application 61/172,289, also in the name of iCeutica Pty Ltd (**Provisional Applications 7**) and all patent applications that:

- (i) claim priority from Provisional Applications 7;
- (ii) disclose or claim the Invention or any aspect of it; or
- (iii) comprise continuations, continuations in part, divisions, re-issue or substitution of the patent applications described in paragraphs (i) and (ii) above and application for a substantially similar form of protection for the Invention granted by another country where the essence is that the holder of the protection gains an exclusive right to make, use and sell a product or process.

**8. Invention: A novel formulation of diclofenac**

Inventors: Aaron Dodd, Felix Meiser, Marck Norett, Adrian Russell and William Bosch

Patent Applications:

Patent application no. PCT/AU2010/000471, filed on 24 April 2010 in the name of iCeutica Pty Ltd, and priority Australian Patent Application No. 2009901748 filed on 24 April 2009 and US Patent Application 61/172,291, also in the name of iCeutica Pty Ltd (**Provisional Applications 8**) and all patent applications that:

- (i) claim priority from Provisional Applications 8;
- (ii) disclose or claim the Invention or any aspect of it; or
- (iii) comprise continuations, continuations in part, divisions, re-issue or substitution of the patent applications described in paragraphs (i) and (ii) above and application for a substantially similar form of protection for the Invention granted by another country where the essence is that the holder of the protection gains an exclusive right to make, use and sell a product or process.

**9. Invention: A novel formulation of indomethacin**

docs 2775373v3 NSIV



Inventors: Aaron Dodd, Felix Meiser, Marck Norett, Adrian Russell and William Bosch

Patent Applications:

Patent application no. PCT/AU2010/000472, filed on 24 April 2010 in the name of iCeutica Pty Ltd, and priority Australian Patent Application No. 2009901745 filed on 24 April 2009 and US Patent Application 61/172,295, also in the name of iCeutica Pty Ltd (**Provisional Applications 9**) and all patent applications that:

- (i) claim priority from Provisional Applications 9;
- (ii) disclose or claim the Invention or any aspect of it; or
- (iii) comprise continuations, continuations in part, divisions, re-issue or substitution of the patent applications described in paragraphs (i) and (ii) above and application for a substantially similar form of protection for the Invention granted by another country where the essence is that the holder of the protection gains an exclusive right to make, use and sell a product or process.

EXECUTED as a deed

Signed Sealed and Delivered by Adrian  
Russell in the presence of:

*Adrian S. Russell*  
Signature

*Blank Hand*  
Signature of witness

*MARCK NORRET*  
Name of witness  
(please print)

Signed Sealed and Delivered by Felix Meiser  
in the presence of:

*Felix Meiser*  
Signature

*Adrian S. Russell*  
Signature of witness

*Adrian Russell*  
Name of witness  
(please print)

Signed Sealed and Delivered by Marck  
Norret in the presence of:

*Blank Hand*  
Signature

*Adrian S. Russell*  
Signature of witness

*Adrian Russell*  
Name of witness  
(please print)

Executed by iCeutica Pty Ltd ACN 113 244 )  
152 in accordance with section 127(1) of the )  
Corporations Act 2001 (Cth): )  
)  
)

*[Signature]*  
Signature of director

*[Signature]*  
Signature of director or company secretary\*  
\*delete whichever does not apply

*MATTHEW CALLAHAN*  
Name (please print)

*LANCE CAMACHO*  
Name (please print)

docs 2775373v3 NSIV

# NOTARIAL CERTIFICATE

State of Minnesota )

) ss.

County of Hennepin )

I hereby certify that attached hereto is a true and correct copy of the Assignment from  
Adrian Russell, Felix Meiser and Marck Norret to iCeutica Pty Ltd, for the listed applications.

Title	Serial Number and filing date	Filing date
Production of encapsulated nanoparticles at high volume fractions	PCT/AU2010/000464	24 April 2010
	AU 2009901744	24 April 2009
	US 61/172,278	24 April 2009
Production of encapsulated nanoparticles at commercial scales	PCT/AU2010/000466	24 April 2010
	AU 2009901740	24 April 2009
	US 61/172,297	24 April 2009
Method for the production of commercial nanoparticle and microparticle powders	PCT/AU2010/000467	24 April 2010
	AU 2009901747	24 April 2009
	US 61/172,300	24 April 2009
Method for improving the dissolution profile of a biologically active material	PCT/AU2010/000465	24 April 2010
	AU 2009901741	24 April 2009
	US 61/172,301	24 April 2009
A novel formulation of metaxalone	PCT/AU2010/000468	24 April 2010
	AU 2009901743	24 April 2009
	US 61/172,281	24 April 2009
A novel formulation of meloxicam	PCT/AU2010/000469	24 April 2010
	AU 2009901742	24 April 2009
	US 61/172,284	24 April 2009
A novel formulation of naproxen	PCT/AU2010/000470	24 April 2010
	AU 2009901746	24 April 2009
	US 61/172,289	24 April 2009
A novel formulation of diclofenac	PCT/AU2010/000471	24 April 2010
	AU 2009901748	24 April 2009
	US 61/172,291	24 April 2009
A novel formulation of indomethacin	PCT/AU2010/000472	24 April 2010
	AU 2009901745	24 April 2009
	US 61/172,295	24 April 2009

Denise Wynn  
Notary Public

(SEAL)

Dated: December 16, 2011

